Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.39 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.39 |
| ▸ | ITGAL | P20701 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | PLG | P00747 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2305347 | 0.81 | KMO (0.47) | KDM1A | |
| SCHEMBL12242089 | 0.80 | KMO (0.43) | KDM1A | |
| SCHEMBL12242080 | 0.79 | SMN1; SMN2 (0.46) | KDM1A | |
| SCHEMBL12242079 | 0.79 | KDM1A (0.44) | KDM1ACNR2 | |
| SCHEMBL12242059 | 0.78 | BCL2L1 (0.42) | KDM1A | |
| SCHEMBL12242082 | 0.78 | MAPK1 (0.47) | KDM1A | |
| SCHEMBL12242054 | 0.78 | RORC (0.43) | KDM1A | |
| SCHEMBL12242068 | 0.78 | KMO (0.41) | KCNH2CNR2 | |
| SCHEMBL12242062 | 0.78 | KDM1A (0.39) | KDM1ACNR2 | |
| SCHEMBL12242091 | 0.78 | SMN1; SMN2 (0.43) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263564-A1 | PYRIDINE, BICYCLIC PYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| EP-2350051-A1 | PYRIDINE, BICYCLIC PYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010056549-A1 | PYRIDINE, BICYCLIC PYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263564-A1 | PYRIDINE, BICYCLIC PYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT6 | CASP6 322/4885TLR8 1597/4885ITGB3 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.